Search

Displaying results 8081 - 8090 of 8143 in total
  1. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Fluocortolone

    go.drugbank.com/drugs/DB08971
    ApprovedWithdrawn

    Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  3. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bio...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  5. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound I...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  6. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in co...

  7. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  8. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Niguldipine

    go.drugbank.com/drugs/DB09239
    Experimental

    Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Niludipine

    go.drugbank.com/drugs/DB09240
    Experimental

    Niludipine is a calcium channel blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates